Published • loading... • Updated
RGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
Investors may seek compensation as the lawsuit alleges Regencell made false statements and hid market-manipulation risk, with a June 23 lead plaintiff deadline.
- Rosen Law Firm and Bronstein, Gewirtz & Grossman, LLC are seeking lead plaintiffs for a securities class action against Regencell Bioscience Holdings Limited, with investors who purchased RGC securities between October 28, 2024, and October 31, 2025, facing a June 23, 2026, application deadline.
- The complaint alleges that Regencell and its officers made materially false and misleading statements regarding business operations, concealing the Company's vulnerability to market manipulation and resulting financial risks to shareholders.
- "Our practice centers on restoring investor capital and ensuring corporate accountability," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC, whose firm has recovered hundreds of millions of dollars for investors nationwide.
- Investors may participate in the class action at no out-of-pocket cost, as the firms operate on a contingency fee basis and invite interested parties to review the complaint or contact legal representatives.
- Serving as lead plaintiff involves directing the litigation on behalf of other class members, though investors retain the right to share in any potential recovery without serving as the lead representative in this case.
Insights by Ground AI
24 Articles
24 Articles
RGC Shareholder Alert: Investors With Losses May Seek to Lead the ...
·Crystal River, United States
Read Full ArticleCoverage Details
Total News Sources24
Leaning Left2Leaning Right3Center8Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
15%
C 62%
R 23%
Factuality
To view factuality data please Upgrade to Premium
